Cargando…

BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody

The therapeutic functionality of the antibodies from phage display is verified after an initial screening. Several immunological assays such as ELISA, flow cytometry, the western blot, and surface plasmon resonance (SPR) assay are commonly used; the IgG-format antibody is usually preferred to verify...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jong Rip, Kim, Min Jung, Tae, Nara, Wi, Tae Min, Kim, Se-Ho, Lee, Eung Suk, Kim, Dae Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354572/
https://www.ncbi.nlm.nih.gov/pubmed/32630442
http://dx.doi.org/10.3390/v12060684
_version_ 1783558115910746112
author Choi, Jong Rip
Kim, Min Jung
Tae, Nara
Wi, Tae Min
Kim, Se-Ho
Lee, Eung Suk
Kim, Dae Hee
author_facet Choi, Jong Rip
Kim, Min Jung
Tae, Nara
Wi, Tae Min
Kim, Se-Ho
Lee, Eung Suk
Kim, Dae Hee
author_sort Choi, Jong Rip
collection PubMed
description The therapeutic functionality of the antibodies from phage display is verified after an initial screening. Several immunological assays such as ELISA, flow cytometry, the western blot, and surface plasmon resonance (SPR) assay are commonly used; the IgG-format antibody is usually preferred to verify the functionality of antibodies, which need elaborative mammalian expression and purification work. Here, we describe a biolayer interferometry (BLI)-based assay that can evaluate the inhibitory functions of antibodies at an earlier stage of screening. To develop a PD-L1-targeting antibody from phage display, we applied the BLI assay to the initial scFv antibody screening, in addition to common ELISA and fluorescence-activated cell sorting (FACS) assays, which showed high advantages and relevance with the in vitro cell-based PD-1/PD-L1 inhibition assay. The same assays for IgG-format antibodies showed high efficiency of the BLI assay in the functional characterization of antibodies, and one candidate selected from the BLI assay resulted in highly efficacious antitumor activity in an in vivo syngeneic mouse study. The BLI assay was also beneficial when searching for antibodies with diverse epitopes. These results demonstrated that the BLI-based inhibition assay is an excellent technique for high-throughput scFv antibody screening in earlier stages and can make phage-display antibody screening more efficient to develop therapeutic candidates.
format Online
Article
Text
id pubmed-7354572
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73545722020-07-23 BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody Choi, Jong Rip Kim, Min Jung Tae, Nara Wi, Tae Min Kim, Se-Ho Lee, Eung Suk Kim, Dae Hee Viruses Article The therapeutic functionality of the antibodies from phage display is verified after an initial screening. Several immunological assays such as ELISA, flow cytometry, the western blot, and surface plasmon resonance (SPR) assay are commonly used; the IgG-format antibody is usually preferred to verify the functionality of antibodies, which need elaborative mammalian expression and purification work. Here, we describe a biolayer interferometry (BLI)-based assay that can evaluate the inhibitory functions of antibodies at an earlier stage of screening. To develop a PD-L1-targeting antibody from phage display, we applied the BLI assay to the initial scFv antibody screening, in addition to common ELISA and fluorescence-activated cell sorting (FACS) assays, which showed high advantages and relevance with the in vitro cell-based PD-1/PD-L1 inhibition assay. The same assays for IgG-format antibodies showed high efficiency of the BLI assay in the functional characterization of antibodies, and one candidate selected from the BLI assay resulted in highly efficacious antitumor activity in an in vivo syngeneic mouse study. The BLI assay was also beneficial when searching for antibodies with diverse epitopes. These results demonstrated that the BLI-based inhibition assay is an excellent technique for high-throughput scFv antibody screening in earlier stages and can make phage-display antibody screening more efficient to develop therapeutic candidates. MDPI 2020-06-25 /pmc/articles/PMC7354572/ /pubmed/32630442 http://dx.doi.org/10.3390/v12060684 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Choi, Jong Rip
Kim, Min Jung
Tae, Nara
Wi, Tae Min
Kim, Se-Ho
Lee, Eung Suk
Kim, Dae Hee
BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody
title BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody
title_full BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody
title_fullStr BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody
title_full_unstemmed BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody
title_short BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody
title_sort bli-based functional assay in phage display benefits the development of a pd-l1-targeting therapeutic antibody
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354572/
https://www.ncbi.nlm.nih.gov/pubmed/32630442
http://dx.doi.org/10.3390/v12060684
work_keys_str_mv AT choijongrip blibasedfunctionalassayinphagedisplaybenefitsthedevelopmentofapdl1targetingtherapeuticantibody
AT kimminjung blibasedfunctionalassayinphagedisplaybenefitsthedevelopmentofapdl1targetingtherapeuticantibody
AT taenara blibasedfunctionalassayinphagedisplaybenefitsthedevelopmentofapdl1targetingtherapeuticantibody
AT witaemin blibasedfunctionalassayinphagedisplaybenefitsthedevelopmentofapdl1targetingtherapeuticantibody
AT kimseho blibasedfunctionalassayinphagedisplaybenefitsthedevelopmentofapdl1targetingtherapeuticantibody
AT leeeungsuk blibasedfunctionalassayinphagedisplaybenefitsthedevelopmentofapdl1targetingtherapeuticantibody
AT kimdaehee blibasedfunctionalassayinphagedisplaybenefitsthedevelopmentofapdl1targetingtherapeuticantibody